VTAMA demonstrated early and consistent response rates in disease severity and itch improvements, measured by the Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™) and Peak ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results